4//SEC Filing
Perry Andrew 4
Accession 0001562180-24-000325
CIK 0001560241other
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 6:03 AM ET
Size
16.2 KB
Accession
0001562180-24-000325
Insider Transaction Report
Form 4
Perry Andrew
Chief Commercial Officer
Transactions
- Sale
Common Stock
2024-01-03$3.12/sh−379$1,182→ 89,136 total - Award
Common Stock
2024-01-03+33,570→ 89,515 total - Award
Stock Options (Right to Buy)
2024-01-03+67,050→ 67,050 totalExercise: $2.97Exp: 2034-01-03→ Common Stock (67,050 underlying) - Sale
Common Stock
2024-01-03$3.12/sh−2,034$6,344→ 87,102 total
Footnotes (8)
- [F1]Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2025 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
- [F2]Each RSU represents a contingent right to receive one share of Issuer common stock.
- [F3]Represents (i) 1,095 shares of common stock; (ii) 3,750 RSUs from award granted on January 3, 2022; (iii) 16,100 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 33,570 RSUs from award granted on January 3, 2024.
- [F4]The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a sell-to-cover transaction and do not represent discretionary transactions by the Reporting Person.
- [F5]The price represents the weighted average price with a low of $3.08 and a high of $3.16. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]Represents (i) 1,466 shares of common stock; (ii) 3,000 RSUs from award granted on January 3, 2022; (iii) 16,100 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 33,570 RSUs from award granted on January 3, 2024.
- [F7]Represents (i) 3,457 shares of common stock; (ii) 3,000 RSUs from award granted on January 3, 2022; (iii) 12,075 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 33,570 RSUs from award granted on January 3, 2024.
- [F8]The shares underlying this option vest as to 25% of the shares on January 3, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
Issuer
G1 Therapeutics, Inc.
CIK 0001560241
Entity typeother
Related Parties
1- filerCIK 0001877793
Filing Metadata
- Form type
- 4
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 6:03 AM ET
- Size
- 16.2 KB